08:42 AM EDT, 08/05/2026 (MT Newswires) -- China-based CSPC Pharmaceutical Group said Wednesday it signed a joint venture agreement with British drugmaker AstraZeneca (AZN.L, AZN.ST) to build a biologics manufacturing facility in Shijiazhuang, China. Under the agreement, CSPC will contribute 51% of the capital, while AstraZeneca will provide the remaining 49%. They will jointly manage the construction and daily operations of the joint venture, which will initially focus on the manufacturing and supply of mutually agreed-upon biologics drug substances.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.